Source link : https://newshealth.biz/health-news/second-anti-her2-tki-approved-for-nsclc/
Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US market. Medscape Medical News Source link : https://www.medscape.com/viewarticle/second-anti-her2-tki-approved-nsclc-2025a1000wan?src=rss Author : Publish date : 2025-11-19 20:59:00 Copyright for syndicated content belongs to the linked Source.
The post Second Anti-HER2 TKI Approved for NSCLC first appeared on News Health.
—-
Author : News Health
Publish date : 2025-11-19 20:59:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8